David Charles Fajgenbaum MD MBA, MSc

PubMed

• 12 citations
  Diagnostic challenges of the idiopathic plasmacytic lymphadenopathy (IPL) subtype of idiopathic multicentric Castleman disease (iMCD): Factors to differentiate from Ig...
  Asami Nishikori, Midori Filiz Nishimura, David C Fajgenbaum, Yoshito Nishimura, Kanna Maehama
  Journal of Clinical Pathology. 2025-12-15
• 1 citations
  International Consensus Histopathological Criteria for Subtyping Idiopathic Multicentric Castleman Disease Based on Machine Learning Analysis.
  Midori Filiz Nishimura, Tomoka Haratake, Yoshito Nishimura, Asami Nishikori, Remi Sumiyoshi
  American Journal of Hematology. 2025-09-01
• 1 citations
  The Involvement of PI3K-Akt Signaling in the Clinical and Pathological Findings of Idiopathic Multicentric Castleman Disease-Thrombocytopenia, Anasarca, Fever, Reticul...
  Tomoka Haratake, Midori Filiz Nishimura, Asami Nishikori, Michael V Gonzalez, Daisuke Ennishi
  Modern Pathology. 2025-08-01

Journal Articles

• Cytokine Storm  
  David Fajgenbaum, MD, The New England Journal of Medicine
• Predictors of Response to Anti‐IL6 Monoclonal Antibody Therapy (Siltuximab) in Idiopathic Multicentric Castleman Disease: Secondary Analyses of Phase II Clinical Trial...  
  David C Fajgenbaum, Craig Tendler, British Journal of Haematology
• International, Evidence-Based Consensus Treatment Guidelines for Idiopathic Multicentric Castleman Disease  
  Aaron Goodman, Corey Casper, Sudipto Mukherjee, Peter Voorhees, Angela Dispenzieri, David C Fajgenbaum, Amy Chadburn, Razelle Kurzrock, Raj Jayanthan, Sunita Nasta, Th..., Blood

Books/Book Chapters

• Hematology/Oncology Clinics of North America: Castleman's Disease 
  Chapter: Castleman Disease Pathogenesis 
  David C. Fajgenbaum & Dustin ShillingEditors: Frits van Rhee, Nikhil C. Munshi.Elsevier2018
• Multiple myeloma, the state of the art 
  Chapter: Castleman Disease 
  Page 259 - 270Amy Y Liu & David C. FajgenbaumEditors: Jorge Vega.Permanyer2017
• We Get It: Voices of Grieving College Students and Young Adults 
  Heather Servaty-Seib & David C. FajgenbaumJessica Kingsley Publishers2015

Abstracts/Posters

• Type I Interferon Response Identified through Phenotypic and Transcriptional Profiling of Circulating Immune Cells during Idiopathic Multicentric Castleman Disease Flare
  David C Fajgenbaum, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Quantitative Changes in Serum Proteins Including CXCL13 Are Early Indicators of Response to Anti-IL6 Therapy in Idiopathic Multicentric Castleman Disease
  David C Fajgenbaum, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Hypercytokine-Producing Cells and Oligoclonal T-Cell Populations in Lymph Nodes from Castleman Disease Patients
  Anna Wiing, Wenzhao Meng, Gerald Wertheim, Dale Frank, Michele Paessler, Megan S. Lim, Eline T. Luning Prak, David C Fajgenbaum, Vinodh Pillai, Blood (ASH Annual Meeting Abstracts), 1/1/2018

Lectures

• Frontiers in Medicine: Personalized Medicine 
  1/1/2019
• MOD1 Genetics Case Presentations 
  1/1/2019
• Overtime: Battling a deadly disease as a physician, researcher, patient, and entrepreneur 
  1/1/2019

Other

• Unicentric Castleman disease 
  David C. Fajgenbaum, UpToDate
  1/1/2018
• HHV-8-associated multicentric Castleman disease 
  David C. Fajgenbaum, UpToDate
  1/1/2018
• HHV-8-negative/idiopathic multicentric Castleman disease 
  David C. Fajgenbaum, UpToDate
  1/1/2018